Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00537095
First received: September 27, 2007
Last updated: January 9, 2013
Last verified: January 2013
Results First Received: April 27, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Thyroid Neoplasms
Interventions: Drug: Vandetanib
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
From September 28th, 2007 to October 16th, 2008, 164 patients were enrolled in the study by 16 centres with a main activity in thyroid cancer in 7 European countries. Among these 164 patients, 145 patients were randomised to receive vandetanib 300 mg once daily oral dose or placebo.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The main reason for non-randomisation was non-respect of eligibility criteria

Reporting Groups
  Description
ZD6474 ZD6474, Vandetanib 300mg
PLACEBO PLACEBO

Participant Flow:   Overall Study
    ZD6474     PLACEBO  
STARTED     72     73  
COMPLETED     21     16  
NOT COMPLETED     51     57  
surgery                 1                 0  
Adverse Event                 24                 4  
disease progression                 21                 48  
Death                 3                 1  
Withdrawal by Subject                 2                 2  
subjective disease progression                 0                 1  
Incorrect enrolment                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ZD6474 ZD6474, Vandetanib 300mg
PLACEBO PLACEBO
Total Total of all reporting groups

Baseline Measures
    ZD6474     PLACEBO     Total  
Number of Participants  
[units: participants]
  72     73     145  
Age  
[units: year]
Mean ± Standard Deviation
  62.8  ± 11.21     63.8  ± 11.59     63  ± 11.4  
Gender  
[units: Participants]
     
Female     33     34     67  
Male     39     39     78  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to Tumor Progression   [ Time Frame: Time from date of randomisation to date of the first documented tumor progression or date of death from any cause (within the 3 months) of tumor assessment ]

2.  Secondary:   Disease Control Rate at 6 Months   [ Time Frame: 6 months after randomisation ]

3.  Secondary:   Objective Response Rate   [ Time Frame: 46.7 months ]

4.  Secondary:   Time to Death   [ Time Frame: time from randomisation to date of death ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description For the efficacy part, 72 were randomized to received ZD6474 and 73 placebo. All For the safety part, 73 patients received at least one dose of ZD6474 and 72 placebo

Reporting Groups
  Description
ZD6474 ZD6474, Vandetanib 300mg
PLACEBO PLACEBO

Serious Adverse Events
    ZD6474     PLACEBO  
Total, serious adverse events      
# participants affected / at risk     19/73 (26.03%)     12/72 (16.67%)  
Blood and lymphatic system disorders      
Lymphadenopathy * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Cardiac disorders      
Angina pectoris * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Arrythmia * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Atrial fibrillation * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Atrioventricular block * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Bradyarrythmia † 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Sinus bradycardia * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Torsade de pointe * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Ventricular tachycardia * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Gastrointestinal disorders      
Diarrhoea * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Inguinal hernia * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Rectal haemorrhage * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Vomiting * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Infections and infestations      
Pneumonia * 1    
# participants affected / at risk     2/73 (2.74%)     1/72 (1.39%)  
Appendicitis * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Bronchopneumonia * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Urinary Tract infection viral * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Injury, poisoning and procedural complications      
Femur fracture * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Tibia fracture * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Investigations      
Electrocardiogramm QT prolonged * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Musculoskeletal and connective tissue disorders      
Arthralgia * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Groin pain * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Muscular weakness * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Nervous system disorders      
Syncope * 1    
# participants affected / at risk     1/73 (1.37%)     1/72 (1.39%)  
Cerebral hemorrage * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Ischemic stroke * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Loss of conciousness * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Monoparesis * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Respiratory, thoracic and mediastinal disorders      
Dyspnea * 1    
# participants affected / at risk     2/73 (2.74%)     0/72 (0.00%)  
Haemoptysis * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Interstitial lung disease * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Lung disorder * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Pleural effusion * 1    
# participants affected / at risk     0/73 (0.00%)     1/72 (1.39%)  
Skin and subcutaneous tissue disorders      
Cutaneous lupus erythematosus * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Photosensitivity reaction * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Rash * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Skin hemorrage * 1    
# participants affected / at risk     1/73 (1.37%)     0/72 (0.00%)  
Events were collected by systematic assessment
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 12.1




  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Gerard Lynch
Organization: AstraZeneca
e-mail: ClinicalTrialTransparency@astrazeneca.com


No publications provided by AstraZeneca

Publications automatically indexed to this study:

Responsible Party: MSD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00537095     History of Changes
Other Study ID Numbers: D4200C00079
Study First Received: September 27, 2007
Results First Received: April 27, 2011
Last Updated: January 9, 2013
Health Authority: Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Belgium: Federal Agency for Medicinal Products and Health Products
Sweden: Medical Products Agency
Portugal: National Pharmacy and Medicines Institute
Spain: Spanish Agency of Medicines
Switzerland: Swissmedic